Korro Bio, Inc.KRROEarnings & Financial Report
Korro Bio, Inc. is a clinical-stage biotechnology company focused on developing innovative RNA editing therapies for rare and severe genetic diseases. It leverages its proprietary oligonucleotide platform to target disease-causing mutations, with core pipelines covering ophthalmology, respiratory and neuromuscular disorder segments, striving to address unmet medical needs for global patients.
KRRO Q4 FY2025 Key Financial Metrics
Revenue
$1.3M
Gross Profit
N/A
Operating Profit
N/A
Net Profit
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
-43.1%
Korro Bio, Inc. Q4 FY2025 Financial Summary
Korro Bio, Inc. reported revenue of $1.3M (down 43.1% YoY) for Q4 FY2025, with a net profit of N/A (down 136.1% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $1.3M |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
Korro Bio, Inc. Annual Revenue by Year
Korro Bio, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $6.4M).
Korro Bio, Inc. Quarterly Revenue & Net Profit History
Korro Bio, Inc. results over the last 7 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.3M | -43.1% | N/A | N/A |
| Q3 FY2025 | $1.1M | — | $-18.1M | -1657.0% |
| Q2 FY2025 | $1.5M | — | $-25.8M | -1765.1% |
| Q1 FY2025 | $2.5M | — | $-23.4M | -917.1% |
| Q3 FY2024 | $0 | — | $-21.0M | N/A |
| Q2 FY2024 | $0 | — | $-21.8M | N/A |
| Q1 FY2024 | $0 | — | $-19.6M | N/A |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $2.5M | $1.5M | $1.1M | $1.3M |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | -43.1% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Assets | $198.0M | $249.6M | $243.5M | $202.2M | $180.4M | $161.6M | $113.5M |
| Liabilities | $46.6M | $51.5M | $63.9M | $63.3M | $65.3M | $62.5M | $62.1M |
| Equity | $151.4M | $198.1M | $179.6M | $139.0M | $115.1M | $99.0M | $51.4M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-21.9M | $-14.6M | $-16.1M | $-24.5M | $-19.2M | $-17.2M | $-78.6M |